OncoPharm Colon Cancer Updates (IDEA & Keynote - 177)
6 snips
Dec 3, 2020 Discover the latest breakthroughs in colon cancer treatment! The conversation highlights the final OS results of the IDEA trial, comparing 3 vs. 6 months of adjuvant chemotherapy. Also explored are the promising findings from the Keynote 177 trial, showcasing the effectiveness of Pembrolizumab for metastatic colorectal cancer with high microsatellite instability. Tune in for expert insights that could change the landscape of colon cancer care!
AI Snips
Chapters
Transcript
Episode notes
IDEA Trial: Treatment Duration Nuances
- The IDEA trial showed that three months of adjuvant chemo might be worse than six months overall, but three months is non-inferior in low-risk patients or those receiving CapeOX.
- This affirms that treatment length should consider risk stratification and chemo regimen choice for stage three colon cancer.
IDEA Five-Year Survival Confirmation
- Five-year overall survival data confirms previous three-year disease-free survival for IDEA trial, showing about 80% cure rate with stage 3 colon cancer.
- Six months of FOLFOX remains the gold standard as no regimen has yet outperformed it in survival outcomes.
Three-Year Disease-Free Milestone
- Achieving three years disease-free after colon cancer treatment indicates a high likelihood of being cured and remaining alive at five years.
- This milestone is a key prognostic indicator clinicians and patients can use to assess long-term outcomes.